36,679 Shares in Boston Scientific Corporation $BSX Purchased by Meeder Advisory Services Inc.

Meeder Advisory Services Inc. purchased a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 36,679 shares of the medical equipment provider’s stock, valued at approximately $1,565,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Kelleher Financial Advisors bought a new position in shares of Boston Scientific during the 2nd quarter worth approximately $25,000. FWL Investment Management LLC bought a new stake in Boston Scientific in the 2nd quarter valued at $26,000. Swiss RE Ltd. acquired a new stake in Boston Scientific during the 4th quarter valued at $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in Boston Scientific during the 4th quarter valued at $26,000. Finally, Clal Insurance Enterprises Holdings Ltd bought a new position in Boston Scientific during the first quarter worth $28,000. Institutional investors own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Stifel Nicolaus set a $60.00 price objective on shares of Boston Scientific in a report on Wednesday, July 29th. Weiss Ratings cut shares of Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, July 7th. Jefferies Financial Group reduced their target price on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a report on Wednesday, June 24th. Oppenheimer decreased their price target on shares of Boston Scientific from $90.00 to $85.00 and set an “outperform” rating on the stock in a research note on Monday, July 27th. Finally, Needham & Company LLC lowered their price target on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a report on Wednesday, July 8th. Twenty-four research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $71.62.

Insider Transactions at Boston Scientific

In related news, Director David C. Habiger purchased 2,100 shares of Boston Scientific stock in a transaction that occurred on Wednesday, August 5th. The shares were acquired at an average price of $47.59 per share, with a total value of $99,939.00. Following the completion of the transaction, the director directly owned 17,160 shares of the company’s stock, valued at $816,644.40. This represents a 13.94% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael F. Mahoney purchased 186,240 shares of Boston Scientific stock in a transaction that occurred on Monday, August 3rd. The shares were bought at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the transaction, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders have acquired 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is currently owned by company insiders.

Boston Scientific Trading Up 3.1%

BSX stock opened at $52.02 on Thursday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The company’s 50-day simple moving average is $46.22 and its 200 day simple moving average is $58.22. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50. The company has a market capitalization of $75.39 billion, a PE ratio of 21.06, a price-to-earnings-growth ratio of 1.10 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business’s revenue was up 7.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, sell-side analysts anticipate that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific announced that its board has initiated a stock repurchase program on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s board believes its stock is undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.